Epidemiological risk factors for hypersensitivity reactions to abacavir

HIV Medicine

Volumn 4, Issue 4, 2003, Pages 321-324

  Easterbrook, Philippa J ^a   Waters, A ^a   Murad, S ^a   Ives, N ^a   Taylor, C ^a   King, D ^b   Vyakarnam, A ^b   Thorburn, D ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Abacavir; Ethnic group; Hypersensitivity

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD8 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; AGE; ARTHRALGIA; ARTICLE; CASE CONTROL STUDY; CAUCASIAN; CELL COUNT; CHILL; CLINICAL ARTICLE; CONJUNCTIVITIS; CONTROLLED STUDY; COUGHING; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG USE; DYSPNEA; EDEMA; ETHNIC DIFFERENCE; FEMALE; FEVER; GENDER; GENETIC ASSOCIATION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALAISE; MALE; MULTIVARIATE ANALYSIS; MYALGIA; PRIORITY JOURNAL; RASH; RISK FACTOR; STOMATITIS; TACHYCARDIA;

ADULT; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HIV INFECTIONS; HUMANS; LYMPHOCYTE COUNT; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK FACTORS;

EID: 0142155195     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2003.00166.x     Document Type: Article

References (9)

1. Hetherington S, McGuirk S, Powell G et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23: 1603-1614.
2. Saag M, Sonnerborg A, Torres RA et al. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. AIDS 1998; 12: F203-F209.
3. Vyakarnam A, King D, Tomkins S et al. Immunological components of hypersensitivity to Abacavir. 8th European Conference on Clinical Aspects and Treatment of HIV Infection. Athens, October 2001 [Abstract 139].
4. Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 2002; 359: 727-732.
5. Hetherington S, Hughes AR, Mosteller M et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359: 1121-1122.
6. Cutrell A, Edwards M, Spreen W et al. Risk factor analysis of hypersensitivity reactions to abacavir introduction. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, July 2001 [Abstract 527].
7. Hernandez J, Williams V, Shaefer M et al. The rate of hypersensitivity reactions to abacavir is similar in under-represented populations and incarcerated subjects. AIDS 2000; 14 (Suppl 4); 569 [Abstract P84].
8. Mazhude C, Jones S, Murad S, Taylor C, Easterbrook P. Female sex but not ethnicity is a strong predictor on non-nucleoside reverse transcriptase inhibitor induced rash. AIDS 2002; 16: 1566-1568.
9. Bersoff-Matcha SJ, Miller WC, Aberg JA et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32: 124-129.